ArticlePharmaceutics2025

Development of Novel Neratinib and Docetaxel Core-Loaded and Trastuzumab Surface-Conjugated Nanoparticle for Treatment of HER-2 Positive Breast Cancer.

Victor Ejigah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.